Among the populations of myeloid cells recruited by dying CRC cell-derived DAMPs in our in vivo experiments, classical monocytic cells (GR-1hiF4/80int–hi) appear to be of specific interest for the priming of anti-tumor immune mechanisms since they have been shown to prime tumor-specific CD8+ T cell responses per se or after intra-tumoral differentiation into potent APCs, respectively (78–80). The gene discussed is CD8A; the disease is neoplasm.